A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.
Also called NCT01174160
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 123 participants
- Sponsor
- Advanz Pharma
- Registry
-
NCT01174160
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01174160. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2015-12-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- vernakalant hydrochloride
- Intervention (Drug)
- Placebo to vernakalent hydrochloride
- Lead sponsor
- Advanz Pharma
Record details
- Record id
cardio:ct-nct01174160- Content hash
630e1925857db60f85adf9e53e871d5b4b7ff59863251baae27fbe3b5999f843